- Home
- PRCT
as 05-30-2025 4:00pm EST
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SAN JOSE |
| Market Cap: | 3.2B | IPO Year: | 2021 |
| Target Price: | $90.00 | AVG Volume (30 days): | 814.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $47.04 - $103.81 | Next Earning Date: | 04-24-2025 |
| Revenue: | $249,121,000 | Revenue Growth: | 59.36% |
| Revenue Growth (this year): | 47.4% | Revenue Growth (next year): | 31.81% |
Stock Insider Trading Activity of PROCEPT BioRobotics Corporation (PRCT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Waters Kevin | PRCT | EVP, CFO | Mar 18 '25 | Sell | $57.06 | 733 | $41,824.98 | 107,991 | |
| Nouri Alaleh | PRCT | EVP, CLO, CORP. SEC. | Mar 18 '25 | Sell | $57.06 | 316 | $18,030.96 | 61,473 | |
| Shiblaq Hisham | PRCT | EVP, Chief Comm. Officer | Mar 18 '25 | Sell | $57.06 | 247 | $14,093.82 | 63,133 | |
| Zadno Reza | PRCT | President, CEO | Mar 18 '25 | Sell | $57.06 | 5,475 | $312,403.50 | 173,070 | |
| Waters Kevin | PRCT | EVP, CFO | Mar 6 '25 | Sell | $61.31 | 3,662 | $224,517.22 | 107,991 | |
| Nouri Alaleh | PRCT | EVP, CLO, CORP. SEC. | Mar 6 '25 | Sell | $61.31 | 3,641 | $223,229.71 | 61,473 | |
| Shiblaq Hisham | PRCT | EVP, Chief Comm. Officer | Mar 6 '25 | Sell | $61.31 | 3,588 | $219,980.28 | 63,133 | |
| Zadno Reza | PRCT | President, CEO | Mar 6 '25 | Sell | $61.31 | 15,916 | $975,809.96 | 173,070 |
Latest PROCEPT BioRobotics Corporation News
PRCT Breaking Stock News: Dive into PRCT Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June
Simply Wall St.
a month ago
Analysts Have Been Trimming Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target After Its Latest Report
GlobeNewswire
a month ago
PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops
MT Newswires
a month ago
Morgan Stanley Cuts Price Target on PROCEPT BioRobotics to $71 From $95, Keeps Overweight Rating
MT Newswires
a month ago
Procept BioRobotics Q1 Net Loss Narrows, Revenue Increases
Zacks
a month ago
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
a month ago
PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
MT Newswires
2 months ago
Truist Cuts Price Target on PROCEPT BioRobotics to $70 From $90, Keeps Buy Rating
Compare PRCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRCT PROCEPT BioRobotics Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.